Page last updated: 2024-12-09

calix(4)arene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

calix(4)arene: a cyclophane consisting of four phenolic units linked by methylene groups; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID562409
SCHEMBL ID1471552
MeSH IDM0336972

Synonyms (38)

Synonym
LS-15229
calix[4]arene
OPREA1_618032
calix[4]arene-25,26,27,28-tetrol, 95%
74568-07-3
tetrahydroxycalix[4]arene
AKOS003615622
SCHEMBL1471552
FT-0623424
W-203703
pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaen
25,26,27,28-tetrahydroxycalix[4]aren
calix(4)arene
J-700384
F1170-0226
pentacyclo[19.3.1.1?,?.1?,??.1??,??]octacosa-1(25),3(28),4,6,9,11,13(27),15(26),16,18,21,23-dodecaene-25,26,27,28-tetrol
mfcd00233673
DTXSID20340197
calix[4]arene-25,26,27,28-tetrol, purum, >=97.0% (hplc)
BBL103831
STL557641
pentacyclo[19.3.1.1~3,7~.1~9,13~.1~15,19~]octacosa-1(25),3(28),4,6,9(27),10,12,15(26),16,18,21,23-dodecaene-25,26,27,28-tetrol
BCP20512
F20552
calix[4]arene, (contains ca. 8 percent chloroform)
calix[4]arene (contains ca. 8% chloroform)
AMY2473
pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3(28),4,6,9(27),10,12,15,17,19(26),21,23-dodecaene-25,26,27,28-tetrol
SY048261
1,3,5,7(1,3)-tetrabenzenacyclooctaphane-12,32,52,72-tetraol
calix(4)arene95
EN300-6743592
pentacyclo[19.3.1.1^{3,7}.1^{9,13}.1^{15,19}]octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-25,26,27,28-tetrol
CS-0197405
123123-29-5
cone-1,3,5,7(1,3)-tetrabenzenacyclooctaphane-12,32,52,72-tetraol
248590-47-8
pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-25,26,27,28-tetrol, stereoisomer

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Peptide based inhibitors of β-amyloid fibrillation are emerging as safe drug candidates as well as interesting compounds for early diagnosis of AD."( Novel Peptide-Calix[4]arene Conjugate Inhibits Aβ Aggregation and Rescues Neurons from Aβ's Oligomers Cytotoxicity
Baglieri, A; Campagna, T; Consoli, GML; Di Natale, G; Giuffrida, ML; Pappalardo, G; Petralia, S; Tosto, R; Zimbone, S, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"Curcumin is an Indian spice with a wide spectrum of biological and pharmacological activities but poor aqueous solubility, rapid degradation, and low bioavailability that affect medical benefits."( Potential Eye Drop Based on a Calix[4]arene Nanoassembly for Curcumin Delivery: Enhanced Drug Solubility, Stability, and Anti-Inflammatory Effect.
Blanco, AR; Consoli, GML; Cordaro, M; Cunsolo, F; Cuzzocrea, S; Esposito, E; Geraci, C; Granata, G; Paterniti, I, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" No immune response occurred when a homologous carrier was used or when a heterologous carrier was applied at a dosage of 10 microg per immunization via intravenous injection."( Conjugation, immunoreactivity, and immunogenicity of calix[4]arenes; model study to potential calix[4]arene-based Ac3+ chelators.
Bos, ES; de Haan, AS; Grote Gansey, MH; Reinhoudt, DN; Verboom, W,
)
0.13
" pH, equilibrium time, shaking speed and sorbent dosage were optimized as 2, 60 min, 125 rpm and 50 mg, respectively."( An efficient calix[4]arene based silica sorbent for the removal of endosulfan from water.
Latif, Y; Memon, N; Memon, S, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (412)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's172 (41.75)29.6817
2010's191 (46.36)24.3611
2020's49 (11.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.76 (24.57)
Research Supply Index6.05 (2.92)
Research Growth Index6.68 (4.65)
Search Engine Demand Index71.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (2.12%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other415 (97.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]